NexGel Reports Clinical Study Data Showing 37.2% Reduction in Hair Density
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
NexGel announced data from the randomized, 30-patient, single-center institutional review board clinical study, funded by Innovative Optics, a supplier of safety products and personal protective equipment for medical, surgical and aesthetic healthcare facilities globally. Positive data from the study detailed a 95.6% reduction in plume concentration compared to the control side. Additionally, at 90 days posttreatment, the interventional site demonstrated a 37.2% mean reduction in hair density versus 26.7% on the control side. Mean pain scores were also significantly lower on the intervention side, with no adverse events were reported.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NXGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NXGL
About NXGL
NexGel, Inc. is a provider of healthcare, beauty, and over-the-counter products, including high-water-content hydrogels. It is engaged in manufacturing high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. It specializes in custom gels by capitalizing on proprietary manufacturing technologies. The Company operates through two segments: NexGel and CGN. Its Nexgel segment comprises the manufacturing of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, which is based in Langhorne, Pennsylvania. Its CGN segment comprises is comprised of the CGN JV used for the Company’s converting and packaging business, which is based in Granbury, Texas. Its brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Silly George. It also holds a portfolio of regenerative biomaterials which include Biovance, Biovance 3L, Natalin, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NEXGEL Reports Q1 Earnings Miss
- Earnings Performance: NEXGEL reported a Q1 GAAP EPS of -$0.11, missing expectations by $0.04, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company posted revenues of $2.65M, a 5.7% year-over-year decrease, falling short of expectations by $1.26M, reflecting challenges from weak market demand and intensified competition.
- Cash Flow Situation: As of March 31, 2026, and December 31, 2025, the company had no cash equivalents, indicating increased liquidity risk that may limit future operational and investment capabilities.
- Future Outlook: Despite the current financial setbacks, NEXGEL anticipates pro forma annual revenue of approximately $35M following the acquisition of Celularity's wound care segment, showcasing potential in strategic transformation.
See More
NEXGEL Appoints New VP of Sales to Drive BIONX Surgical Division Growth
- Key Appointment: NEXGEL has appointed Dave Hazard as Vice President of Sales for BIONX Surgical, leveraging over 13 years of sales leadership in biologics to drive commercial growth in the newly formed division.
- Sales Infrastructure Development: Hazard successfully built a salesforce of over 400 representatives at Nuo Therapeutics and secured a white label partnership with Smith+Nephew, showcasing his ability to establish scalable sales infrastructure that will underpin revenue growth for BIONX Surgical.
- Strategic Partnerships: His experience at Arthrex, where he led a biologics business generating over $50 million annually, positions him well to enhance BIONX Surgical's competitive edge, as Arthrex is also a current strategic partner.
- Product Innovation and Market Opportunities: Hazard noted that NEXGEL and BIONX Surgical possess a world-class portfolio with several new products in the pipeline, which are expected to drive strong market demand across sports medicine, orthopedics, and wound care sectors.
See More
NEXGEL to Report Q1 2026 Financial Results on May 15
- Earnings Release Schedule: NEXGEL will report its financial results for Q1 2026 on May 15, 2026, providing insights into the company's performance in healthcare and consumer products, which is expected to deliver critical financial data and market outlook for investors.
- Conference Call Timing: Following the earnings release, the company will host a conference call at 12:00 P.M. ET on the same day, allowing investors to dial in at 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) to receive real-time updates on the company's latest developments.
- Replay Service: For those unable to attend the live call, NEXGEL offers a replay service available until May 29, 2026, accessible by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International), ensuring widespread dissemination of information.
- Company Background: NEXGEL is a leading provider of healthcare and consumer products, specializing in ultra-gentle, high-water-content hydrogel products, with over 20 years of R&D and manufacturing experience, featuring brands like SilverSeal® and Hexagels®, showcasing its strong competitive position in the industry.
See More
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
NEXGEL NAMES IAN BLACKMAN AS CFO
New Appointment: A new Chief Financial Officer has been appointed at NEXGEL, a company focused on innovative gel technologies.
Leadership Impact: The appointment is expected to enhance the company's financial strategies and overall growth trajectory.
Company Background: NEXGEL specializes in developing advanced gel products for various applications, including healthcare and consumer markets.
Future Prospects: The new CFO's experience is anticipated to drive financial performance and support the company's expansion plans.
See More
NEXGEL's Acquisition of Celularity's Segment to Drive Profitability
- Transaction Closure: NEXGEL has successfully acquired Celularity's degenerative wound segment, expected to boost annual revenue to approximately $35 million, marking a transformation into a more scalable and diversified medical technology company, enhancing market competitiveness.
- New Division Launch: The company has established the BioNX Surgical division, focusing on advanced biomaterials for tendon repair, soft tissue reconstruction, and wound care, which is anticipated to drive commercial growth in new product lines.
- Optimized Financing Structure: The transaction secured a $5.5 million investment through convertible notes with a conversion price of $0.60 and 50% warrant coverage, expected to enhance the company's financial stability and operational capabilities.
- Positive Profit Outlook: Management anticipates that the acquisition will lead to immediate profitability, with EBITDA expected to be positive post-integration, reflecting strong market demand and growth potential in the new product lines.
See More
NEXGEL Reports Q1 Earnings Miss
- Earnings Performance: NEXGEL reported a Q1 GAAP EPS of -$0.11, missing expectations by $0.04, indicating ongoing pressure on profitability that could undermine investor confidence.
- Revenue Decline: The company posted revenues of $2.65M, a 5.7% year-over-year decrease, falling short of expectations by $1.26M, reflecting challenges from weak market demand and intensified competition.
- Cash Flow Situation: As of March 31, 2026, and December 31, 2025, the company had no cash equivalents, indicating increased liquidity risk that may limit future operational and investment capabilities.
- Future Outlook: Despite the current financial setbacks, NEXGEL anticipates pro forma annual revenue of approximately $35M following the acquisition of Celularity's wound care segment, showcasing potential in strategic transformation.
See More
NEXGEL Appoints New VP of Sales to Drive BIONX Surgical Division Growth
- Key Appointment: NEXGEL has appointed Dave Hazard as Vice President of Sales for BIONX Surgical, leveraging over 13 years of sales leadership in biologics to drive commercial growth in the newly formed division.
- Sales Infrastructure Development: Hazard successfully built a salesforce of over 400 representatives at Nuo Therapeutics and secured a white label partnership with Smith+Nephew, showcasing his ability to establish scalable sales infrastructure that will underpin revenue growth for BIONX Surgical.
- Strategic Partnerships: His experience at Arthrex, where he led a biologics business generating over $50 million annually, positions him well to enhance BIONX Surgical's competitive edge, as Arthrex is also a current strategic partner.
- Product Innovation and Market Opportunities: Hazard noted that NEXGEL and BIONX Surgical possess a world-class portfolio with several new products in the pipeline, which are expected to drive strong market demand across sports medicine, orthopedics, and wound care sectors.
See More
NEXGEL to Report Q1 2026 Financial Results on May 15
- Earnings Release Schedule: NEXGEL will report its financial results for Q1 2026 on May 15, 2026, providing insights into the company's performance in healthcare and consumer products, which is expected to deliver critical financial data and market outlook for investors.
- Conference Call Timing: Following the earnings release, the company will host a conference call at 12:00 P.M. ET on the same day, allowing investors to dial in at 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) to receive real-time updates on the company's latest developments.
- Replay Service: For those unable to attend the live call, NEXGEL offers a replay service available until May 29, 2026, accessible by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International), ensuring widespread dissemination of information.
- Company Background: NEXGEL is a leading provider of healthcare and consumer products, specializing in ultra-gentle, high-water-content hydrogel products, with over 20 years of R&D and manufacturing experience, featuring brands like SilverSeal® and Hexagels®, showcasing its strong competitive position in the industry.
See More
NEXGEL Appoints New CFO to Integrate Acquisition and Accelerate Growth
- Executive Appointment: NEXGEL has appointed Ian Blackman as Chief Financial Officer, leveraging his over 30 years of experience in luxury and consumer sectors to drive the integration of the Celularity acquisition, which is expected to enhance the company's financial foundation and operational efficiency.
- Acquisition Integration Strategy: Blackman's appointment coincides with NEXGEL's final agreement with Celularity, anticipated to strengthen the company's market competitiveness and drive long-term shareholder value through the integration of regenerative medicine assets.
- Performance Enhancement: During his tenure at McIntosh Group, Blackman successfully grew revenue by over 90% and EBITDA by over 335%, and his extensive financial management experience will provide robust support for NEXGEL's future growth.
- Market Opportunities: NEXGEL's hydrogel technology platform and expanding commercial footprint present significant growth opportunities for stakeholders, and Blackman's addition will help optimize financial reporting processes and enhance the company's overall financial performance.
See More
NEXGEL NAMES IAN BLACKMAN AS CFO
New Appointment: A new Chief Financial Officer has been appointed at NEXGEL, a company focused on innovative gel technologies.
Leadership Impact: The appointment is expected to enhance the company's financial strategies and overall growth trajectory.
Company Background: NEXGEL specializes in developing advanced gel products for various applications, including healthcare and consumer markets.
Future Prospects: The new CFO's experience is anticipated to drive financial performance and support the company's expansion plans.
See More
NEXGEL's Acquisition of Celularity's Segment to Drive Profitability
- Transaction Closure: NEXGEL has successfully acquired Celularity's degenerative wound segment, expected to boost annual revenue to approximately $35 million, marking a transformation into a more scalable and diversified medical technology company, enhancing market competitiveness.
- New Division Launch: The company has established the BioNX Surgical division, focusing on advanced biomaterials for tendon repair, soft tissue reconstruction, and wound care, which is anticipated to drive commercial growth in new product lines.
- Optimized Financing Structure: The transaction secured a $5.5 million investment through convertible notes with a conversion price of $0.60 and 50% warrant coverage, expected to enhance the company's financial stability and operational capabilities.
- Positive Profit Outlook: Management anticipates that the acquisition will lead to immediate profitability, with EBITDA expected to be positive post-integration, reflecting strong market demand and growth potential in the new product lines.
See More
